Ocular Pain (Eye Pain) is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Ocular Pain (Eye Pain) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Ocular Pain (Eye Pain) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ocular Pain (Eye Pain) overview
Ocular pain, commonly known as eye pain, refers to discomfort or soreness within or around the eye. It can stem from various sources, including eye strain, dry eyes, infections, injuries, or underlying conditions like glaucoma or corneal abrasions. The pain may present as aching, burning, stabbing, or a sensation of foreign objects in the eye. Accompanying symptoms could include redness, light sensitivity, blurred vision, or tearing. Diagnosis involves a comprehensive eye examination by an ophthalmologist to identify the root cause. Treatments may include prescription eye drops, antibiotics for infections, artificial tears for dry eyes, or surgical interventions depending on the underlying condition, emphasizing the importance of timely and accurate diagnosis for effective management.
For a complete picture of PTSR and LoA scores for drugs in Ocular Pain (Eye Pain), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
